NCT02512562 - A Study to Evaluate the Effect of ACH-3102 and Simeprevir on AL-335 Pharmacokinetics in Healthy Volunteers | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 31, 2015

Primary Completion Date

August 31, 2015

Study Completion Date

August 31, 2015

Conditions

Chronic Hepatitis C

Interventions

DRUG

AL-335

AL-335 is a prodrug being developed as an orally administered anti-HCV therapeutic.

DRUG

ACH-3102

ACH-3102 is an NS5A inhibitor being developed as an orally administered anti-HCV therapeutic.

DRUG

Simeprevir

Simeprevir is an orally active, small molecule inhibitor of the NS3/4A protease of HCV and indicated for the treatment of chronic HCV infection as a component of a combination antiviral treatment regimen.

Trial Locations (1)

Unknown

Biotrial, Rennes